Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
-0.11 |
N/A |
N/A |
N/A |
2024-08-12 |
2024-06 |
-0.11 |
-0.12 |
-0.01 |
-9.09% |
2024-05-09 |
2024-03 |
-0.1 |
-0.11 |
-0.01 |
-10.00% |
2024-03-07 |
2023-12 |
-0.11 |
-0.09 |
0.02 |
18.18% |
2023-11-09 |
2023-09 |
-0.07 |
-0.1 |
-0.03 |
-42.86% |
2023-08-10 |
2023-06 |
-0.08 |
-0.07 |
0.01 |
12.50% |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-16 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-04-03 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-04-02 |
Jefferies |
Downgrade |
Buy |
Hold |
2021-03-15 |
Piper Sandler |
Upgrade |
|
Overweight |
2021-03-14 |
Oppenheimer |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2023-07-16 |
BASKETT FOREST |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-12-27 |
ELAM NEVAN C |
Director |
22.50K |
Sale |
2023-12-13 |
HAWKINS RICHARD JAMES |
Director |
35.24K |
Stock Award(Grant) |
2023-12-27 |
LOWRANCE DAVID L. CPA |
Chief Financial Officer |
342.36K |
Sale |
2023-12-13 |
LUTZ ROBERT MATTHEW |
Chief Operating Officer |
300.00K |
Stock Award(Grant) |
2023-12-13 |
MCCRACKEN JOSEPH S |
Director |
190.84K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
NEA Management Company, LLC |
24.14M |
77.12M |
17.86% |
2023-06-29 |
Bain Capital Life Sciences Investors, LLC |
11.62M |
37.13M |
8.60% |
2023-06-29 |
Farallon Capital Management Llc |
10.91M |
34.85M |
8.07% |
2023-06-29 |
VR Adviser, LLC |
6.35M |
20.29M |
4.70% |
2023-06-29 |
Adage Capital Partners GP L.L.C. |
6.06M |
19.38M |
4.49% |
2023-06-29 |
Caxton Corporation |
4.98M |
15.91M |
3.68% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.26M |
10.40M |
2.41% |
2023-08-30 |
PGIM Jennison Health Sciences Fd |
2.33M |
8.45M |
1.73% |
2023-08-30 |
iShares Russell 2000 ETF |
1.69M |
6.11M |
1.25% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.22M |
3.89M |
0.90% |
2023-07-30 |
Fidelity Small Cap Index Fund |
674.41K |
2.41M |
0.50% |
2023-08-30 |
iShares Russell 2000 Value ETF |
643.58K |
2.33M |
0.48% |
Split |
Date |
0 : 1 |
2017-04-28 |
0.04 : 1 |
2010-04-26 |